Aileron Therapeutics Inc (ALRN) Expected to Post Earnings of -$0.46 Per Share

Wall Street brokerages predict that Aileron Therapeutics Inc (NASDAQ:ALRN) will report ($0.46) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Aileron Therapeutics’ earnings. The highest EPS estimate is ($0.43) and the lowest is ($0.48). The business is expected to issue its next quarterly earnings results on Thursday, February 8th.

On average, analysts expect that Aileron Therapeutics will report full year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($1.80) to ($1.73). For the next year, analysts anticipate that the company will report earnings of ($2.07) per share, with EPS estimates ranging from ($2.36) to ($1.76). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that follow Aileron Therapeutics.

Aileron Therapeutics (NASDAQ:ALRN) last posted its earnings results on Thursday, November 9th. The company reported ($0.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.07).

Separately, Zacks Investment Research upgraded Aileron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Aileron Therapeutics currently has an average rating of “Buy” and an average price target of $19.33.

In related news, major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $9.80, for a total value of $1,470,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System purchased a new stake in shares of Aileron Therapeutics in the 3rd quarter valued at $110,000. Vanguard Group Inc. purchased a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at $111,000. Tudor Investment Corp ET AL purchased a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at $112,000. Bank of New York Mellon Corp acquired a new position in Aileron Therapeutics during the 3rd quarter worth $135,000. Finally, Citadel Advisors LLC acquired a new position in Aileron Therapeutics during the 2nd quarter worth $141,000. Hedge funds and other institutional investors own 7.55% of the company’s stock.

Shares of Aileron Therapeutics (NASDAQ ALRN) opened at $9.33 on Tuesday. Aileron Therapeutics has a 1 year low of $8.77 and a 1 year high of $15.48.

TRADEMARK VIOLATION NOTICE: This story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2018/01/30/aileron-therapeutics-inc-alrn-expected-to-post-earnings-of-0-46-per-share.html.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply